

IFW



Please Direct All Correspondence to Customer Number **20995**

TRANSMITTAL LETTER
INFORMATION DISCLOSURE STATEMENT


Applicant : Weber et al.
App. No : 10/828,795
Filed : April 21, 2004
For : COMPOSITIONS FOR AFFECTING
WEIGHT LOSS
Examiner : Sharon Brooks
Art Unit : 1614

CERTIFICATE OF MAILING

I hereby certify that this correspondence and all marked attachments are being deposited with the United States Postal Service as first-class mail in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, on

June 27, 2005

(Date)


Sam K. Tahmassebi, Reg. No. 45,151


Mail Stop Amendment

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Dear Sir:

Enclosed for filing in the above-identified application are:

- (X) An Information Disclosure Statement and PTO/SB/08 equivalent listing references for consideration:
 - (X) Listing 36 references.
 - (X) Enclosing 30 references.
- (X) The Commissioner is hereby authorized to charge any additional fees which may be required, or credit any overpayment, to Account No. 11-1410.
- (X) Return prepaid postcard.


Sam K. Tahmassebi
Registration No.
Attorney of Record
Customer No. 20,995
(619) 235-8550



INFORMATION DISCLOSURE STATEMENT


Applicant : Weber et al.
App. No : 10/828,795
Filed : April 21, 2004
For : COMPOSITIONS FOR AFFECTING
WEIGHT LOSS
Examiner : Sharon Brooks
Art Unit : 1614

CERTIFICATE OF MAILING

I hereby certify that this correspondence and all marked attachments are being deposited with the United States Postal Service as first-class mail in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, on

June 27, 2005

(Date)


Sam K. Tahmassebi, Reg. No. 45,151

Mail Stop Amendment
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Dear Sir:

Enclosed for filing in the above-identified application is a PTO/SB/08 Equivalent listing 36 references to be considered by the Examiner. Also enclosed are 30 foreign patent references and/or non-patent literature as listed on the Information Disclosure Statement.

This Information Disclosure Statement is being filed before the receipt of a first Office Action on the merits, and presumably no fee is required. If a first Office Action on the merits was mailed before the mailing date of this Statement, the Commissioner is authorized to charge the fee set forth in 37 C.F.R. § 1.17(p) to Deposit Account No. 11-1410.


Respectfully submitted,

KNOBBE, MARTENS, OLSON & BEAR, LLP

Dated: June 27, 2005

By: 

Sam K. Tahmassebi
Registration No. 45,151
Attorney of Record
Customer No. 20,995
(619) 235-8550

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

Application No.	10/828,795
Filing Date	April 21, 2004
First Named Inventor	Weber et al.
Art Unit	1614
Examiner	Sharon Brooks
Attorney Docket No.	OREX.001A

(Multiple sheets used when necessary)

SHEET 1 OF 2

U.S. PATENT DOCUMENTS

Examiner Initials	Cite No.	Document Number Number - Kind Code (if known) Example: 1,234,567 B1	Publication Date MM-DD-YYYY	Name of Patentee or Applicant	Pages, Columns, Lines Where Relevant Passages or Relevant Figures Appear
	1	5,512,593	04/30/96	Dante	
	2	5,817,665	10/06/98	Dante	
	3	5,856,332	01/05/99	Dante	
	4	5,958,962	09/28/99	Cook	
	5	6,034,091	03/07/00	Dante	
	6	2004/0122033	06/24/04	Nargund et al.	

NON PATENT LITERATURE DOCUMENTS

Examiner Initials	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ¹
	7	Zhang et al. "Positional cloning of the mouse obese gene and its humane homologue," <i>Nature</i> 372:425-432 (1994).	
	8	Devlin et al. <i>Int. J. Eating Disord.</i> 28:325-332 (2000).	
	9	Cone et al. "The arcuate nucleus as a conduit for diverse signals relevant to energy homeostasis," <i>Int'l Journal of Obesity</i> , 25(5):S63-S67 (2001).	
	10	Saper et al. "The need to feed: Homeostatic and hedonic control of eating," <i>Neuron</i> , 36:199-211 (2002).	
	11	Korner et al. "The emerging science of body weight regulation and its impact on obesity treatment," <i>J. Clin. Invest.</i> , 111(5):565-570 (2003).	
	12	Portoghese, P.S. <i>J. Med. Chem.</i> , 35:1927 (1992).	
	13	Carroll, F.I. <i>J. Med. Chem.</i> , 46:10 (2003).	
	14	Glass et al. <i>Neuropeptides</i> , 33:350 (1999).	
	15	Schmidhammer et al. <i>A. Helv. Chim. Acta</i> , 77:999 (1994).	
	16	Hahn et al. " <i>J. Pharm. Exper. Therapeutics</i> , 235:846-850 (1985).	
	17	Kolb et al. <i>A. Pharmaceutical Res.</i> , 6:266-271 (1985).	
	18	Pasternak et al. <i>J. of Med. Chem.</i> , 23:674-676 (1980).	

Examiner Signature

Date Considered

***Examiner:** Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

T¹ - Place a check mark in this area when an English language Translation is attached.

INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Multiple sheets used when necessary)</i>	Application No.	10/828,795
	Filing Date	April 21, 2004
	First Named Inventor	Weber et al.
	Art Unit	1614
	Examiner	Sharon Brooks
SHEET 2 OF 2	Attorney Docket No.	OREX.001A

NON PATENT LITERATURE DOCUMENTS

Examiner Initials	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ¹
	19	Le Bourdonnec et al. <i>J. Med. Chem.</i> , 43:2489-2492 (2000).	
	20	Sayre et al. <i>J. Med. Chem.</i> , 27:1325 (1984).	
	21	Erez et al. <i>J. Med. Chem.</i> , 25:847-849 (1982).	
	22	Dechant et al. <i>Drugs</i> , 41:225-253 (1991).	
	23	Tamiz et al. <i>J. Am. Chem. Soc.</i> , 122:5393-5394 (2000).	
	24	Tamiz et al. <i>J. Med. Chem.</i> , 44:1615:1622 (2001).	
	25	Hussey et al. <i>J. Am. Chem. Soc.</i> , 125:3692-3693 (2003).	
	26	Portoghese et al. <i>Life Sci.</i> , 31:1283-1286 (1982).	
	27	Portoghese et al. <i>J. Med. Chem.</i> , 29:1855-1861 (1986).	
	28	Stepinski et al. <i>Internat. J. of Peptide & Protein Res.</i> , 38:588-592 (1991).	
	29	Parr et al. <i>J. Immunol.</i> , 169:856-864 (2002).	
	30	Klok et al. <i>Macromolecules</i> , 35:746-759 (2002).	
	31	Portoghese et al. <i>J. Med. Chem.</i> , 29:1650-1653 (1986).	
	32	Sashiwa et al. <i>Macromolecules</i> , 33:6913 (2000).	
	33	Ninan et al. <i>Tetrahedron.</i> , 48:6709:16 (1992).	
	34	Zeng et al. <i>Tetrahedron Lett.</i> , 29:5123 (1988).	
	35	<i>Remington's Pharmaceutical Sciences</i> . 18 th Edition; Easton, PA: Mack Publishing Co. (1990).	
	36	Fingl et al. <i>The Pharmacological Basis of Therapeutics</i> . Ch.1, pp 1. (1975).	

1787941
062405

Examiner Signature	Date Considered
<p>*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.</p>	

T¹ - Place a check mark in this area when an English language Translation is attached.